Autopsy report · NCT06943664
Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer
Cause of deathFunding or business
“Lack of funding”
Life of this trial
- Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.
Vital statistics
- Status
- Withdrawn
- Phase
- Phase 2
- Sponsor
- Roswell Park Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage IIIB Lung Cancer AJCC v8; Stage IIIC Lung Cancer AJCC v8; Stage IV Lung Cancer AJCC v8
- Interventions
- Biospecimen Collection; Cemiplimab; Cetuximab Sarotalocan Sodium; Computed Tomography; Electronic Health Record Review; Endobronchial Ultrasound Bronchoscopy
- Participants
- 0
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.